This article discusses the retiring of Ph. Eur. and USP heavy metal assays as well as a means of updating related specifications with minimal regulatory burden.
Andrew Teasdale
Advertisement
Andrew Teasdale, PhD, is a Principle Scientist at AstraZeneca.
Articles by Andrew Teasdale
The authors support the retiring of Ph. Eur. and USP heavy metal assays and propose a means of updating related specifications with minimal regulatory burden.
The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.
Current guidance for absorption of elemental impurities does not address dermal exposure, resulting in a simplistic approach to limit setting.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Advertisement
Latest Updated Articles
Implementation of ICH Q3D Elemental Impurities Guideline: Challenges and OpportunitiesPublished: March 2nd 2015 | Updated:
Establishing Limits for Dermal Absorption of Elemental ImpuritiesPublished: September 2nd 2015 | Updated:
EMA Guideline on Setting Health-Based Exposure LimitsPublished: December 2nd 2015 | Updated:
Pharma Collaboration Proposes Retirement of Obsolete Heavy Metals TestsPublished: September 1st 2018 | Updated:
- Retirement for Obsolete Heavy Metals Tests
Published: October 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First
2
PharmTech Weekly News Roundup – Week of December 1, 2025
3
BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation
4
Immortal Dragons Will Help Etheros Target Aging and Related Diseases
5
